A phase 2b, randomized, blinded,placebo-controlled trial investigating the efficacy and safety of visugromabversus placebo, both in combination with pembrolizumab, pemetrexed, andcis-/carboplatin, in participants with newly diagnosed metastatic non-squamousnon-small cell lung cancer (GDFATHER-LUNG-01)